INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. & Encou...
September 14 2018 - 6:07PM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces that it is investigating claims on behalf of
investors of Global Blood Therapeutics, Inc. (“Global Blood” or
“the Company”) (NASDAQ: GBT) for violations of §§10(b) and 20(a) of
the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false
and/or misleading statements and/or failed to disclose information
pertinent to investors. Stat published an article about Global
Blood, claiming that there are “important risks that investors
might be glossing over” about the likelihood of Global Blood’s new
drug for sickle cell disease, voxelotor, being approved by the FDA.
The article refers to recent results of a Phase 3 clinical trial,
stating “Global Blood lacks data demonstrating voxelotor reduces
the frequency of crises,” a typically necessary requirement for FDA
approval for sickle cell disease. The article also asserted, “[i]n
the Phase 3 study, voxelotor did not improve the quality of life of
sickle cell patients.” Based on this article, Global Blood’s share
price fell more than 7% on the same day.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180914005603/en/
The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian,
Esq.310-301-3335info@schallfirm.comwww.schallfirm.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024